27 March 2024
Chaarat Gold Holdings Limited
("Chaarat" or "the Company")
Tulkubash Gold Project Financing Update
Chaarat (AIM: CGH), a mining explorer and developer with projects in the Kyrgyz Republic, advises shareholders that, further to its recent announcements, financing discussions regarding its Tulkubash Gold Project in the Kyrgyz Republic ("Tulkubash") continue with various parties, including, as previously announced, Xiwang International.
There is no certainty at this stage that the ongoing financing discussions will be completed, and further announcements will be made as and when appropriate.
Enquiries
Chaarat Gold Holdings Limited | +44 (0)20 7499 2612 |
David Mackenzie (Chief Financial Officer) | |
|
|
Strand Hanson Limited (Nominated Adviser) | +44 (0)20 7409 3494 |
Ritchie Balmer / James Spinney / Robert Collins |
|
| |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0)20 7886 2500 |
Hugh Rich
| |
Axis Capital Markets Limited (Joint Broker) | +44 (0)20 3026 0449 |
Ben Tadd / Lewis Jones |
|
|
|
St Brides Partners Limited (Financial Public Relations) | +44 (0)20 7236 1177 |
Susie Geliher / Isabelle Morris |
|
|
|
About Chaarat
Chaarat is an exploration and development company which is advancing the Tulkubash and Kyzyltash Gold Projects in the Kyrgyz Republic. The Company has a clear strategy to build a leading emerging markets gold company through organic growth and selective M&A.
Chaarat aims to create value for its shareholders, employees and communities from its high-quality gold and mineral deposits by building relationships based on trust and operating to the best environmental, social and employment standards.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.